How is humira supplied

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. These cases have had a very aggressive disease course and have been fatal.

The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Rheumatoid Arthritis: HUMIRA is indicated, alone or in combination with methotrexate or other non-biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.

Juvenile Idiopathic Arthritis: HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Psoriatic Arthritis: HUMIRA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.

Ulcerative Colitis: HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. HUMIRA is a prescription medicine used to treat non-infectious intermediate middle part of the eye , posterior back of the eye , and panuveitis all parts of the eye in adults and children 2 years of age and older. Moderate to Severe Pediatric Ulcerative Colitis.

Moderate to Severe Juvenile Idiopathic Arthritis. Moderate to Severe Hidradenitis Suppurativa in Adolescents 12 years and older. Non-Infectious Intermediate, Posterior, and Panuveitis. Patients residing in or receiving treatment in certain states may not be eligible. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This assistance offer is not health insurance.

Arava and Plaquenil are registered trademarks of their respective owners. Step 1. Step 2. Step 3. What to tell your patients who are transitioning from the original presentation. Uveitis Referral and Prescription Form. Updating your EMR List and how to prescribe. Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis 1 The recommended HUMIRA Citrate-free dose regimen for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis is shown below:.

Indications 1 Rheumatoid Arthritis: HUMIRA is indicated, alone or in combination with methotrexate or other non-biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.

A patient may self-inject HUMIRA after appropriate training and monitoring by a healthcare professional Prior to initiating HUMIRA and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection In clinical trials, the most common adverse reaction was injection site reactions.

Most were mild and did not necessitate discontinuation Anaphylaxis or serious allergic reactions may occur. Indication 1 Uveitis: HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

Indications 1 Juvenile Idiopathic Arthritis: HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Patients with TB have frequently presented with disseminated or extrapulmonary disease.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

If an infection develops, monitor carefully and initiate appropriate therapy. Drug interactions with biologic products: A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker.

An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA.

Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun. Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach abdomen. These problems can lead to liver failure and death. Psoriasis new or worsening.

Symptoms include red scaly patches or raised bumps that are filled with pus. Remember, tell your doctor right away if you have an infection or symptoms of an infection, including: Fever, sweats, or chills Muscle aches Cough Shortness of breath Blood in phlegm Weight loss Warm, red, or painful skin or sores on your body Diarrhea or stomach pain Burning when you urinate Urinating more often than normal Feeling very tired HUMIRA is given by injection under the skin.

HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities. Moderate to severe polyarticular juvenile idiopathic arthritis JIA in children 2 years of age and older.

Psoriatic arthritis PsA in adults. Ankylosing spondylitis AS in adults. Moderate to severe hidradenitis suppurativa HS in people 12 years and older. To treat moderate to severe ulcerative colitis UC in adults and children 5 years of age and older. To treat moderate to severe chronic plaque psoriasis Ps in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

To treat non-infectious intermediate middle part of the eye , posterior back of the eye , and panuveitis all parts of the eye in adults and children 2 years of age and older. Reference: 1. Leaving AbbVie Web Site. Do you wish to leave this site?